The headline numbers for Sarepta Therapeutics (SRPT) give insight into how the company performed in the quarter ended December 2023, but it may be worthwhile to compare some of its key metrics to Wall

Is It Too Late to Buy Sarepta Therapeutics Stock?

07:15am, Wednesday, 28'th Feb 2024

Sarepta Therapeutics faced some issues last year, but it earned approval for an important medicine. The biotech is on the verge of another key regulatory nod that should help improve its financial res

Why Earnings Season Could Be Great for Sarepta Therapeutics (SRPT)

09:51am, Tuesday, 27'th Feb 2024

Sarepta Therapeutics (SRPT) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Sarepta (SRPT) to Report Q4 Earnings: Will It Beat Estimates?

12:25pm, Wednesday, 21'st Feb 2024

Investors' focus will likely be on Sarepta's (SRPT) product sales of its recently-approved DMD gene therapy when it reports fourth-quarter earnings.

Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2023 Financial Results

08:30am, Wednesday, 21'st Feb 2024

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report fourth quarter and full-year 2023 financial results

Sarepta Therapeutics (SRPT) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release

11:06am, Tuesday, 20'th Feb 2024

Sarepta Therapeutics (SRPT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Sarepta's (SRPT) DMD Drug sBLA Gets FDA's Priority Tag, Stock Up

07:31am, Monday, 19'th Feb 2024

Sarepta (SRPT) announces the FDA's acceptance of its efficacy supplement to the Elevidys BLA, seeking to expand the treatment label for its DMD drug. The stock gains 8%.

Sarepta Therapeutics (SRPT) Moves 7.8% Higher: Will This Strength Last?

04:31am, Monday, 19'th Feb 2024

Sarepta Therapeutics (SRPT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the n

Why Sarepta Therapeutics Stock Is Soaring Today

11:23am, Friday, 16'th Feb 2024

The U.S. FDA accepted Sarepta's efficacy supplement filing for DMD gene therapy Elevidys. This filing could lead to the removal of age and ambulation restrictions for Elevidys.

U.S. FDA to not conduct advisers' meet for Sarepta's Duchenne gene therapy

07:23am, Friday, 16'th Feb 2024

Sarepta Therapeutics said on Friday that the U.S. FDA will not conduct a meeting of its advisers and will do a priority review for traditional approval of its gene therapy Elevidys for a muscle wastin

Gene therapy: Why does it cost millions for a single treatment?

07:01am, Thursday, 15'th Feb 2024

Gene therapy treatments have been making major headlines as advances in gene editing have gone mainstream thanks to the advent of CRISPR/Cas-9 technology. The shot heard around the world in the medic

5 Biotech Stocks to Consider for Your Portfolio in 2024

10:00am, Tuesday, 13'th Feb 2024

New drug approvals and pipeline progress are likely to help maintain momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and solid pipeline progress position SRPT, EXEL, IMCR,

Top Fintech Company

featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by